Literature DB >> 34918325

COVID-19 in Immunocompromised Patients: A Systematic Review.

Anna Stainer1,2, Francesco Amati1,2, Giulia Suigo2, Edoardo Simonetta3,4, Andrea Gramegna3,4, Antonio Voza1,5, Stefano Aliberti1,2.   

Abstract

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) was first identified as a novel coronavirus in Wuhan, Hubei province, central China, in December 2019, and is responsible for the 2019-to-present pandemic. According to the most recent data released by the World Health Organization, more than 200 million people have been infected by SARS-CoV-2 so far, and more than 4 million people died worldwide. Although our knowledge on SARS-CoV-2 and COVID-19 is constantly growing, data on COVID-19 in immunocompromised patients are still limited. The aim of the present systematic review is to describe clinical picture, disease severity, proposed treatment regimen, and response to vaccination in patients with different types and severity of immunosuppression. Thieme. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34918325     DOI: 10.1055/s-0041-1740110

Source DB:  PubMed          Journal:  Semin Respir Crit Care Med        ISSN: 1069-3424            Impact factor:   3.119


  1 in total

1.  Protective SARS-CoV-2 Antibody Response in Children With Inflammatory Bowel Disease.

Authors:  Luca Bosa; Costanza Di Chiara; Paola Gaio; Chiara Cosma; Andrea Padoan; Sandra Cozzani; Giorgio Perilongo; Mario Plebani; Carlo Giaquinto; Daniele Donà; Mara Cananzi
Journal:  Front Pediatr       Date:  2022-02-10       Impact factor: 3.418

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.